Predictions
Acadia Pharmaceuticals
Start price
Target price
Perf. (%)
€29.00
14.07.23
14.07.23
€29.37
14.07.24
14.07.24
-51.64%
24.05.24
24.05.24
Acadia Pharmaceuticals
Start price
Target price
Perf. (%)
€26.40
14.07.23
14.07.23
€29.39
14.07.24
14.07.24
-46.88%
24.05.24
24.05.24
PTC Therapeutics Inc.
Start price
Target price
Perf. (%)
€35.60
13.07.23
13.07.23
€65.28
13.07.24
13.07.24
-12.92%
23.05.24
23.05.24
Arrowhead Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€30.89
13.07.23
13.07.23
€80.49
13.07.24
13.07.24
-26.48%
24.05.24
24.05.24
Canopy Growth Corp
Start price
Target price
Perf. (%)
€0.44
08.07.23
08.07.23
€1.00
08.07.24
08.07.24
6.71%
19.12.23
19.12.23
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€6.50
01.07.23
01.07.23
-
01.07.24
01.07.24
41.83%
24.05.24
24.05.24
Ascendis Ph.sp.adr 1 Dk 1
Start price
Target price
Perf. (%)
€79.00
24.06.23
24.06.23
€150.00
31.08.25
31.08.25
49.37%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€7.14
24.06.23
24.06.23
€9.00
30.11.25
30.11.25
29.16%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year
Sage Therapeutics Inc.
Start price
Target price
Perf. (%)
€44.20
24.06.23
24.06.23
€60.00
31.12.25
31.12.25
-74.66%
22.05.24
22.05.24
Could be very worthwhile Investment >20% year
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€48.20
06.06.23
06.06.23
€74.95
06.06.24
06.06.24
-22.41%
24.05.24
24.05.24
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€7.97
30.05.23
30.05.23
€15.85
30.05.24
30.05.24
15.65%
24.05.24
24.05.24
Taro Pharmaceutical Industries Ltd
Start price
Target price
Perf. (%)
€31.00
28.05.23
28.05.23
-
28.05.24
28.05.24
27.10%
23.05.24
23.05.24
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€208.80
07.09.22
07.09.22
€300.00
31.12.24
31.12.24
-34.75%
24.05.24
24.05.24
Could be very worthwhile Investment >20% year